Yan Li

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

Timothy A. Yap, Yan Li, Amita Patnaik et al. · Journal of Clinical Oncology · 2011 · 543 citations

Medicine, Oncology, Pharmacology +17

AMPylation of Rho GTPases by <i>Vibrio</i> VopS Disrupts Effector Binding and Downstream Signaling

Melanie L. Yarbrough, Yan Li, Lisa N. Kinch et al. · Science · 2008 · 362 citations

Life Sciences, Microbiology, Molecular Biology +17

CRISPR Reveals a Distal Super-Enhancer Required for Sox2 Expression in Mouse Embryonic Stem Cells

Yan Li, Chloe M. Rivera, Haruhiko Ishii et al. · PLoS ONE · 2014 · 221 citations · Full text

Life Sciences, Genetics, Molecular Biology +17

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

L. Rhoda Molife, Yan Li, Joanna Vitfell-Rasmussen et al. · Journal of Hematology & Oncology · 2014 · 190 citations · Full text

Medicine, Oncology, Pharmacology +17

Elevating CXCR7 Improves Angiogenic Function of EPCs via Akt/GSK-3β/Fyn-Mediated Nrf2 Activation in Diabetic Limb Ischemia

Xiaozhen Dai, Xiaoqing Yan, Jun Zeng et al. · Circulation Research · 2017 · 168 citations · Full text

Life Sciences, Cell Biology, Molecular Medicine +16